title: Captopril potentiates the anticonvulsant activity of carbamazepine and lamotrigine in the mouse maximal electroshock seizure model.
abstract: Some studies suggest a higher risk of hypertension in people with epilepsy. Captopril, a potent and selective angiotensin-converting enzyme (ACE) inhibitor, is a well known antihypertensive drug. Besides the peripheral renin-angiotensin system (RAS), ACE inhibitors are also suggested to affect the brain RAS which might participate in the regulation of seizure susceptibility. The purpose of the current study was to evaluate the effect of captopril on the protective action of numerous antiepileptic drugs (carbamazepine [CBZ], phenytoin [PHT], valproate [VPA], phenobarbital [PB], oxcarbazepine [OXC], lamotrigine [LTG] and topiramate [TPM]) against maximal electroshock-induced seizures in mice. This study was accompanied by an evaluation of adverse effects of combined treatment with captopril and antiepileptic drugs in the passive avoidance task and chimney test. Captopril (25 and 50 mg/kg i.p.) did not influence the threshold for electroconvulsions. Among the tested antiepileptics, captopril (25 and 50 mg/kg i.p.) potentiated the antiseizure action of CBZ, decreasing its ED(50) value from 12.1 to 8.9 and 8.7 mg/kg, respectively. Moreover, captopril (50 mg/kg i.p.) enhanced the anticonvulsant activity of LTG. ED(50) value for LTG was lowered from 5.1 to 3.5 mg/kg. The observed interactions between captopril and CBZ or LTG were pharmacodynamic in nature as captopril did not alter plasma and total brain concentrations of these antiepileptics. The combinations of captopril with antiepileptic drugs did not lead to retention deficits in the passive avoidance task or motor impairment in the chimney test. Based on the current preclinical data, it is suggested that captopril may positively interact with CBZ and LTG in epileptic patients. The combinations of captopril with the remaining antiepileptics (PHT, VPA, PB, OXC and TPM) seem neutral.
authors: Department of Physiopathology, Institute of Agricultural Medicine, Jaczewskiego 2, 20-090 Lublin, Poland. lukaw@mp.pl
authors: Krzysztof
authors: K
authors: Lukawski
authors: Tomasz
authors: T
authors: Jakubus
authors: Grzegorz
authors: G
authors: Raszewski
authors: Stanisław J
authors: SJ
authors: Czuczwar
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000819:agonists*; D000959:Antihypertensive Agents / Q000494:pharmacology; D002216:Captopril / Q000494:pharmacology*; D004195:Disease Models, Animal; D004597:Electroshock / Q000009:adverse effects* / Q000379:methods; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D051379:Mice
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000927:Anticonvulsants; D000959:Antihypertensive Agents; D002216:Captopril